Vanta Bioscience Ltd
Incorporated in 2016, Vanta Bioscience
Ltd is in the business of Preclinical Activities.[1]
- Market Cap ₹ 40.0 Cr.
- Current Price ₹ 63.4
- High / Low ₹ 102 / 37.0
- Stock P/E
- Book Value ₹ 26.9
- Dividend Yield 0.00 %
- ROCE -5.82 %
- ROE -31.2 %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of -8.70% over last 3 years.
- Debtor days have increased from 80.4 to 123 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Miscellaneous Industry: Miscellaneous
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| 12 | 14 | 10 | 9 | 6 | |
| 9 | 9 | 6 | 6 | 8 | |
| Operating Profit | 3 | 4 | 4 | 3 | -2 |
| OPM % | 27% | 32% | 40% | 37% | -41% |
| 0 | 0 | 0 | 0 | 1 | |
| Interest | 2 | 2 | 2 | 2 | 6 |
| Depreciation | 1 | 1 | 1 | 1 | 3 |
| Profit before tax | 1 | 1 | 1 | 0 | -10 |
| Tax % | 36% | 25% | 24% | 41% | -2% |
| 1 | 1 | 0 | 0 | -10 | |
| EPS in Rs | 1.11 | 1.58 | 0.71 | 0.14 | -10.27 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -25% |
| TTM: | -38% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -7300% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -20% |
| 3 Years: | -29% |
| 1 Year: | 11% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -9% |
| Last Year: | -31% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves | 16 | 17 | 18 | 18 | 11 | 11 |
| 13 | 17 | 36 | 45 | 57 | 57 | |
| 4 | 8 | 10 | 13 | 10 | 11 | |
| Total Liabilities | 39 | 49 | 70 | 81 | 85 | 85 |
| 18 | 21 | 29 | 36 | 57 | 68 | |
| CWIP | 4 | 7 | 19 | 28 | 11 | 0 |
| Investments | 2 | 0 | 0 | 0 | 0 | 0 |
| 15 | 21 | 21 | 17 | 17 | 17 | |
| Total Assets | 39 | 49 | 70 | 81 | 85 | 85 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| -1 | 2 | 7 | 5 | -1 | |
| -6 | -8 | -22 | -17 | -6 | |
| 10 | 2 | 18 | 10 | 6 | |
| Net Cash Flow | 3 | -3 | 2 | -2 | -0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Debtor Days | 47 | 37 | 75 | 44 | 123 |
| Inventory Days | |||||
| Days Payable | |||||
| Cash Conversion Cycle | 47 | 37 | 75 | 44 | 123 |
| Working Capital Days | 261 | 310 | 245 | 306 | 468 |
| ROCE % | 8% | 5% | 4% | -6% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
2 Apr - Receipt of order worth Rs. 1.2 Cr for technical studies
- Appointment of Company Secretary and Compliance Officer 1 Apr
- Closure of Trading Window 30 Mar
-
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
1 Dec 2023 - Receipt of order worth Rs. 57 Lakh for GLP Studies
- Change In Designation Of Dr. Vyasmurti Madhavrao Shingatgeri (DIN 07728757) From Whole Time Director To Non-Executive Director W.E.F 14.11.2023. 14 Nov 2023
Business Overview:[1]
The company is a preclinical contract research organization, offering preclinical safety assessment services for clientele from the Pharmaceutical, Medical Devices, Nutraceuticals, Feed additives, Biotech, Agrochemicals, Cosmetics, and Chemical industries. In addition, the company also provides risk assessment services for evaluating the safety of Active Pharmaceutical Ingredients (API), excipients, extractable and leachable including pharmaceutical impurities resulting due to manufacturing process or degradation
of the product. VBS also provides expert services for the determination of health-based exposure limits e.g. permitted daily exposure or allowable daily exposure (ADE) including occupational exposure limits (OEL) for pharmaceutical manufacturers.
Services Offered:
a) Toxicology[2]
b) Agro-chemical and Chemical Safety[3]
c) Bio Compatibility Studies[4]
d) Diet Formulation[5]
e) Batch Release Test[6]
f) Medical Devices[7]
g) Food Additives[8]
h) Cosmetics[9]